Epstein-Barr-Virus-Induced One-Carbon Metabolism Drives B Cell Transformation

Liang Wei Wang(Harvard University), Hongying Shen(Center for Systems Biology), Luís Nobre(University of Cambridge), Ina Ersing(Brigham and Women's Hospital), João A. Paulo(Harvard University), Stephen J. Trudeau(Brigham and Women's Hospital), Zhonghao Wang(West China Hospital of Sichuan University), Nicholas A. Smith(Brigham and Women's Hospital), Yijie Ma(Brigham and Women's Hospital), Bryn Reinstadler(Center for Systems Biology), Jason Nomburg(Harvard University), Thomas Sommermann(Brigham and Women's Hospital), Ellen Cahir-McFarland(Brigham and Women's Hospital), Steven P. Gygi(Harvard University), Vamsi K. Mootha(Center for Systems Biology), Michael P. Weekes(University of Cambridge), Benjamin E. Gewurz(Broad Institute)
Cell Metabolism
June 27, 2019
Cited by 198Open Access
Full Text

Abstract

Epstein-Barr virus (EBV) causes Burkitt, Hodgkin, and post-transplant B cell lymphomas. How EBV remodels metabolic pathways to support rapid B cell outgrowth remains largely unknown. To gain insights, primary human B cells were profiled by tandem-mass-tag-based proteomics at rest and at nine time points after infection; >8,000 host and 29 viral proteins were quantified, revealing mitochondrial remodeling and induction of one-carbon (1C) metabolism. EBV-encoded EBNA2 and its target MYC were required for upregulation of the central mitochondrial 1C enzyme MTHFD2, which played key roles in EBV-driven B cell growth and survival. MTHFD2 was critical for maintaining elevated NADPH levels in infected cells, and oxidation of mitochondrial NADPH diminished B cell proliferation. Tracing studies underscored contributions of 1C to nucleotide synthesis, NADPH production, and redox defense. EBV upregulated import and synthesis of serine to augment 1C flux. Our results highlight EBV-induced 1C as a potential therapeutic target and provide a new paradigm for viral onco-metabolism.


Related Papers

No related papers found

Powered by citation graph analysis